Elevation Oncology, Inc. logo

Elevation Oncology, Inc.

NASDAQ:ELEV

Overview | Financials
Company Name Elevation Oncology, Inc.
Symbol ELEV
Currency USD
Price 2.64
Market Cap 144,245,112
Dividend Yield 0%
52-week-range 0.363 - 5.83
Industry Biotechnology
Sector Healthcare
CEO Mr. Joseph J. Ferra Jr.
Website https://elevationoncology.com

An error occurred while fetching data.

About Elevation Oncology, Inc.

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors

Related Stocks

Evelo Biosciences, Inc. logo

Evelo Biosciences, Inc.

EVLO

0 USD

NRx Pharmaceuticals, Inc. logo

NRx Pharmaceuticals, Inc.

NRXP

2.33 USD

Daré Bioscience, Inc. logo

Daré Bioscience, Inc.

DARE

3.54 USD

Passage Bio, Inc. logo

Passage Bio, Inc.

PASG

0.9 USD

Financials

Numbers are in millions USD

Numbers are in millions USD